Guggenheim analyst Vamil Divan reiterated a Buy rating and $140.00 price target on Merck (NYSE: MRK).The analyst commented: "MRK is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE